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Background: cGMP-degrading phosphodiesterase 6 (PDE6) mutations cause around 4 to 5% of retinitis pigmentosa
(RP), a rare form of retinal dystrophy. Growing evidence suggests that inflammation is involved in the progression
of RP. The aims of this study were to corroborate the presence of high TNFα concentration in the eyes of RP
patients and to evaluate whether the blockade of TNFα with Infliximab, a monoclonal anti-TNFα antibody,
prevented retinal degeneration induced by PDE6 inhibition in cultures of porcine retina.
Methods: Aqueous humor from 30 patients with RP and 13 healthy controls were used to quantify the
inflammatory mediators IL-6, TNFα, IL-1β, IL-10 by a multiplex enzyme-linked immunosorbent assay (ELISA) system.
Retinal explants from pig were exposed to Zaprinast, a PDE6 inhibitor, for 24 hours in the absence or the presence
of Infliximab. Cell death was evaluated by TUNEL assay. The number and distribution of caspase-3 positive cells,
indirect poly(ADP)ribose polymerase (PARP) activation and glial fibrillary acidic protein (GFAP) content were visualized
by immunolabeling. Antioxidant total capacity, nitrites and thiobarbituric acid reactive substances (TBARS) formation
were determined to evaluate antioxidant-oxidant status.
Results: IL-6 and TNFα concentrations were higher in the aqueous humor of RP patients than in controls. Infliximab
prevented retinal degeneration, as judging by the reduced presence of TUNEL-positive cells, the reduction of
caspase-3 activation and also reduction of glial activation, in an ex vivo model of porcine retina. Additionally,
Infliximab partially reduced oxidative stress in retinal explants exposed to Zaprinast.
Conclusions: Inflammatory mediators IL-6 and TNFα were elevated in the aqueous humor of RP patients corroborating
previous studies suggesting sustained chronic inflammation. Our study suggests that TNFα is playing an important role
in cell death in an ex vivo model of retinal degeneration by activating different cell pathways at different cell layers of
the retina that should be further studied.
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pigmentosa, Photoreceptor deathBackground
Retinitis pigmentosa (RP) is a common form of rod-cone
dystrophy, constituting the largest Mendelian genetic
cause of blindness in the developed world. Patients with
RP typically loose night vision in adolescence, peripheral
vision in young adulthood, and central vision later in life
due to progressive loss of rod and cone photoreceptor cells.
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available in this article, unless otherwise stateddegeneration and eventually cone cell death that is the
major problem affecting RP patients, because it leads
to loss of central vision [1]. More than 60 genes,
including phosphodiesterase 6 (PDE6) subunit genes,
have been identified to date that, when mutated,
cause different forms of non-syndromic RP [2-7].
Although RP is a genetic disease, increasing evidence
in patients and animal models suggests that oxidative
stress and inflammation, especially TNFα, contribute to
its pathogenesis, independently of the genes mutated
[8-10]. Some reports show the presence of sustained
chronic inflammatory reaction including elevated TNFαl.; licensee BioMed Central Ltd. This is an Open Access article distributed under
n License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
.
Table 1 Description of the participants included in the study
Control RP
Number of subjects 13 30
Males 7 21
Females 6 9
Age (years) 60 ± 3 48 ± 2
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TNFα is a pleiotropic cytokine essential for the induction
and maintenance of the inflammatory immune responses
[13] that is also upregulated in inflammatory ocular
diseases, including Adamantiades-Behcet disease [14],
retinal vascular tumors [15], neovascular age-related
macular degeneration [16], uveitis [17], glaucoma [18]
and ischemic retinopathy [19].
TNFα mediates a broad range of cellular activities,
including proliferation, survival, differentiation, inflamma-
tion and cell death. In the retina, TNFα is likely to be
secreted from activated macrophages, astrocytes, microglial
cells and retinal Müller glial cells. TNFα can trigger several
well-characterized death-promoting (caspase-dependent and
caspase-independent cell death) and survival-promoting
pathways, depending upon the predominating signaling
pathway in the particular cell type [20]. TNFα binding to cell
surface receptors such as TNFR1 mediates activation
of initiator caspases (caspase-8, caspase-10) and finally
triggers cleavage of effector caspases (extrinsic pathway of
cell death) [21]. TNFα is also involved in the intrinsic
pathway of cell death that is initiated by cellular and DNA
damage which particularly involves mitochondria. Finally,
TNFα can also activate a subset of programmed necrosis
called necroptosis. The mechanism that leads cells to
undergo apoptosis or necroptosis and the mechanism that
mediates the execution of necroptosis still remains unclear.
The poly(ADP-ribose) polymerase (PARP) pathway can also
activate this mode of programmed necrosis. PARP-1
activation in response to excessive DNA damage results in
the massive synthesis of poly(ADP-ribose) polymers (PAR),
NAD+ depletion and subsequent release of apoptosis
inducing factor (AIF) from mitochondria, which
translocates to the nucleus where it forms an active
DNA-degrading complex (caspase-independent pathway).
The PARP pathway has been considered as an integral
part of TNF-induced necroptosis; however, it has been
recently described that both pathways represent distinct
and independent routes to programmed necrosis [22].
The mechanisms responsible for photoreceptor cell death
in RP are still unclear. However, increasing evidence
suggests that inflammation [11,12,23,24] and especially
TNFα could contribute to the pathogenesis of RP. There-
fore, inhibition of TNFα and downstream cellular signaling
mechanisms, following interaction of TNFα with its
receptors, could be a possible target in the treatment
of retinal neurodegenerative disorders such as RP.
In the current study we found that IL-6 and TNFα
were increased in the aqueous humor of RP patients.
We also observed that pharmacological inhibition of
TNFα with Infliximab, a specific monoclonal antibody
against TNFα, prevented retinal degeneration in cultures of
porcine retina exposed to Zaprinast. This model reproduces
some events of the degeneration found in murine modelsof RP caused by non-functional PDE6 [25]. We also
observed in our model a reduction of caspase-3 activation,
GFAP reactivity and partially oxidative stress, caused by
Infliximab treatment. These results suggest that inflamma-
tion, especially TNFα upregulation, is playing an important
role in retinal degeneration and, importantly, that strategies
that promote its blockade could be promising therapies.
Methods
Participants in the study
Human samples were obtained, informed consent from
all subjects previously having been given. The procedure
was in accordance with the tenets of the Declaration of
Helsinki and was approved by the IRB of La Fe University
Hospital (Valencia, Spain). Thirty adult patients with
typical forms of RP characterized by an elevated final
dark-adaptation threshold, retinal arteriolar narrowing, and
a reduced and delayed electroretinogram were enrolled in
the study. Thirteen Caucasian patients suffering from
cataracts without any other ocular disease served as controls.
Further details of the patients enrolled in the study
are shown in Table 1.
Patients diagnosed of RP were recruited from Retina
Comunidad Valenciana - Asociación Afectados por
Retinosis Pigmentaria and also from the department of
Ophthalmology of La Fe University Hospital (Valencia,
Spain). Healthy controls were recruited from La Fe
University Hospital (Valencia, Spain).
Ophthalmic examination
The best-corrected visual acuity (BCVA) and automated
visual field (VF) were measured in RP patients as previously
described [8]. Individual data for each patient is shown in
Additional file 1: Table S1. Macular edema secondary to RP
was only present in one patient.
Aqueous humor extraction
Aqueous humor samples from 30 RP patients and from
13 patients with cataracts without any other ocular disease
(controls) were collected as previously described [8].
Undiluted aqueous humor samples were collected
from each patient, placed in sterile tubes, and stored
immediately at −80°C until use. All specimens were assayed
to evaluate cytokine concentration in a double-blind
arrangement with respect to their group. For each patient,
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severe retinopathy.
Cytokine levels in aqueous humor
The concentrations of cytokines in aqueous humor were
measured using a multiplex enzyme-linked immunosorb-
ent assay (ELISA) system. To measure the concentrations
of IL-1β, IL-6, IL-10 and TNFα, the SearchLight
Custom Human Cytokine-Inflammation Q-Plex Array
(Aushon Biosystems, MA, USA) was used. Array was used
according to the manufacturer’s instructions. The signal of
the cytokine array was determined by a cooled CCD
camera (Fujifilm, Tokyo, Japan) using chemiluminescence.
SearchLight CCD Imaging and Analysis System were used
to quantify cytokine concentrations. The cytokine levels
were expressed as pg/mL.
Porcine retinal explant cultures
Seventy eyes (both left and right eyes from each animal)
from small miniature pigs aged 3 to 7 months were
obtained from the local slaughterhouse. Neuroretinal
explants were carried out as recently described [25].
Treatments were added the day of the culture and
maintained for 24 hours. To inhibit PDE6 and induce
retinal degeneration, we used a final concentration of
100 nmol/L Zaprinast [25,26]. Zaprinast (Sigma-Aldrich,
Madrid, Spain) was diluted in dimethyl sulfoxide (DMSO)
(AppliChem, Darmstadt, Germany). The equivalent amount
of DMSO was added to the culture medium of controls. To
evaluate the possible neuroprotective effect of TNFα
blockade we used Infliximab (2 μg/mL, alone or com-
bined with Zaprinast) as TNFα blocker (Remicade®,
Schering-Plough, Madrid, Spain). Infliximab is a chimeric
human immunoglobulin G1 with a mouse variable frag-
ment having high TNFα affinity and neutralizing capacity.
Tissue processing and histology
Retinal explants were fixed in 4% filtered paraformaldehyde
(Sigma-Aldrich, Madrid, Spain) in 0.1 M PBS (pH 7.4) and
cryoprotected in a saccharose gradient (15-20-30%)
(Panreac Química, Barcelona, Spain). Samples were
frozen embedded in Tissue-Tek® OCT™ Compound (Sakura
Finetek Europe BV, Zoeterwoude, The Netherlands).
After this, 10-μm sections were cut with a cryostat
(Leica CM1900, Nussloch, Germany) and placed on
Super Frost Ultra Plus treated slides (Thermo Scientific,
Barcelona, Spain).
TUNEL assay
To evaluate apoptosis the terminal deoxynucleotidil trans-
ferase dUTP nick and labeling (TUNEL) assay was used as
previously described [25]. The apoptotic (TUNEL-positive)
nuclei per field were counted in at least three fields per ret-
inal explant using NIS-Elements imaging software (NIKONInstruments, Badhoevedorp, The Netherlands). The num-
ber of apoptotic nuclei was normalized to the SYTOX
Green-labeled cell nuclei. Results are given as percentage
of apoptotic nuclei/total nuclei. Data are expressed as
mean ± SEM.
Immunofluorescence of caspase-3, GFAP and PAR
Immunofluorescence was carried out on 10-μm cryosec-
tions. Sections were post-fixed for 15 minutes at room
temperature in 4% filtered paraformaldehyde (Sigma-
Aldrich, Madrid, Spain) in 0.1 M PBS (pH 7.4). Sections
were incubated for 1 hour in blocking solution containing
5% normal goat serum, 1% BSA and 0.25% Triton X-100.
They were then incubated with primary antibody against
cleaved caspase-3 (1:200, Cell Signaling Technology,
Barcelona, Spain), glial fibrillary acidic protein (GFAP,
1:400, Sigma-Aldrich, Madrid, Spain) or PAR (1:200, Enzo
Life Science, Madrid, Spain) overnight at 4°C in blocking
solution. After this samples were incubated for one hour at
room temperature with the fluorescence-conjugated
secondary antibody Alexa Fluor 647 (Invitrogen, Life
Technologies, Madrid, Spain) and observed under a
confocal microscope (Leica TCS SP5 Confocal microscope,
Leica Microsistemas SLU, Barcelona, Spain) belonging to
the Microscopy Unit of the IIS-La Fe (Valencia, Spain).
Cells were counted at 40× magnification, and the number
of caspase-3 positive cells was counted manually in 4 fields
per retinal explant. The number of cells positive for
the cleaved caspase-3 immunolabeling was normalized
to the SYTOX Green-labeled cell nuclei (Molecular
Probes, Paisley, UK). Results are given as percentage
of caspase-3 positive cell/total nuclei. Data are expressed
as mean ± SEM.
GFAP and PAR positive cells were difficult to count in
different retinal layers. For the quantification we used the
following formula to calculate the corrected fluorescence
(CF) for each cell layer [27]:
CF ¼ Integrateddensity of theselectedarea
‐ areaof selectedarea meanfluorescenceof backgroundð Þ
Data are expressed as mean ± SEM.
For co-localization of cleaved caspase-3 (combined with
Alexa Fluor 647) and PAR (combined with Alexa Fluor
488 (Invitrogen, Life Technologies, Madrid, Spain))
staining was followed by TUNEL staining.
caspase-3 activity assay
caspase-3 activity was measured with a colorimetric
tetrapeptide (DEVD-pNA) cleavage assay kit following
the manufacturer’s instructions (Bio-Vision, Mountain
View, CA, USA). Total retinal protein was extracted from
retinal explants and measured by the bicinchoninic acid
Table 2 Protein levels of cytokines in aqueous humor
from retinitis pigmentosa (RP) patients and healthy
controls
Control RP
TNF-α (pg/mL) 1.1 ± 0.2 1.7 ± 0.2
95% CI (0.8 to 1.4) (1.4 to 2.0)
Detectable samples 13/13 28/30
IL-6 (pg/mL) 10.8 ± 3.4 23.5 ± 3.8
95% CI (3.2- to 18.5) (15.8 to 31.3)
Detectable samples 13/13 30/30
Note: values are expressed as mean ± SEM; CI: confidence interval.
Figure 1 Relation between visual field and TNFα concentration in
aqueous humor of retinitis pigmentosa (RP) patients. Statistical
analysis revealed a positive relation between visual field and TNFα
values controlling the other predictive variables (sex, age and acuity).
Ninety-five percent confidence intervals are defined by dotted lines.
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arbitrary units (au)/mg of protein.
Nitrites and nitrates (NOX) determination
Intracellular nitrites (stable end-product of nitric oxide
(NO)) and nitrates (NOX) were measured in retinal
explants by spectrophotometric GRIESS reaction using
nitrate reductase [28]. The tissue NOX levels were expressed
as nmol/mg protein.
Oxidative stress evaluation
Retinal explants were assayed for total antioxidant
capacity (TAC) and thiobarbituric acid reactive substances
(TBARS) formation as indicator of malonyldialdehyde
(MDA) formation.
Retinal explants were homogenized in 5 mM phosphate
buffer pH 7, 0.9% NaCl, 0.1% glucose, centrifuged at
10,000 × g for 15 minutes at 4°C, and then the supernatants
were used to determine TAC and TBARS. Protein concen-
trations were measured by the BCA protein assay.
TAC was measured using a commercial kit (Cayman
Chemical, Ann Arbor, MI, USA) [29]. The tissue TAC
levels were expressed as nmol/mg protein.
MDA levels were detected by a colorimetric method
involving thiobarbituric acid (TBA) adduct formation
(Cayman Chemical, Ann Arbor, MI, USA). Tissue TBARS
levels were expressed as nmol/mg protein.
Values for caspase-3 activity, NOX and oxidative markers
are given as the mean ± SEM of at least eight different
cultures. For each experiment samples were measured in
duplicate.
Statistical analyses
All statistical analyses were done using R software
(version 2.15.3) (Foundation for Statistical Computing,
Vienna, Austria). Multivariate analysis of covariance
(MANCOVA) and multiple linear regression models
were used to analyze human data. For parametric
data, ANOVA followed by Newman-Keuls post hoc test
was used. For non-parametric data, Kruskal-Wallis test
followed by Dunn’s Multiple Comparison test was used.
Significance levels were set at α =0.05.
Results
Increased levels of TNFα and IL-6 in aqueous humor of
RP patients
We performed a multiplex ELISA to determine the
concentration of TNFα, IL-6, IL-1β and IL-10 in
aqueous humor of RP patients. IL-1β and IL-10 were
below detectable levels. Descriptive statistics of the results
of the measurements of IL-6 and TNFα are shown in
Table 2. We performed a MANCOVA with the results of
TNFα and IL-6 as dependent variables while disease, age
and gender were taken as predictive variables.This analysis revealed that RP significantly increased
inflammatory mediators IL-6 and TNFα in aqueous
humor (P = 0.03) (See Additional file 2: Table S2). We
found no statistical evidence for gender or age effects.
Further analysis of each of the response variables
indicated that IL-6 is increased in RP patients (P = 0.018).
TNFα showed a tendency to increase in RP patients
(P = 0.09). We assessed the possible association between
inflammatory status (measured as TNFα and IL-6 levels)
and stage of the disease (measured as VF and BCVA
values) using a MANOVA with VF, BCVA, sex and
age as predictors and TNFα and IL-6 levels as re-
sponse variables. Our results showed no evidence of
association between VF and BCVA and inflammatory
status (P = 0.09 for VF and P = 0.94 for visual acuity).
Additionally, we also analyzed separately the associa-
tions among these predictor variables and each of the
two cytokine using linear models. In these analyses we
found a statistically significant association between
higher VF values and higher levels of TNFα (P = 0.03)
(Figure 1).
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cultured porcine retina
We previously described that PDE6 inhibition by Zaprinast
triggered retinal degeneration and induced oxidative stress
and inflammatory mediators such as TNFα and IL-6 in
cultured porcine retina after 24 hours. In particular, TNFα
and IL-6 content increased to twice control content [25].
We tested whether incubation with 2 μg/mL Infliximab,
a TNFα blocker, for 24 hours prevented Zaprinast-induced
retinal degeneration. Firstly, we checked the effect of
Infliximab on the TNFα signaling cascade. As we
could not measure TNFα, because Infliximab interferes
with the ELISA assay as previously described [30], we
evaluated its receptor TNF-R1 whose activation is involved
in multiple apoptotic pathways. TNF-R1 relative expression
increased up to 1.36 ± 0.08 arbitrary units (ANOVA
Newman-Keuls post-test, P <0.0001) in Zaprinast-treated
explants compared to control explants (1.00 ± 0.08 arbitrary
units). However, Infliximab normalized Zaprinast-induced
overexpression of TNF-R1 (0.90 ± 0.08 arbitrary units,Figure 2 Infliximab prevents Zaprinast-induced cell death in cultured
sulfoxide (DMSO), Zaprinast and Infliximab alone or combined with Zaprina
retinal sections showing TUNEL-stained sections visualizing apoptotic phot
accumulation (pink) (C) in SYTOX Green-counterstained retinal sections. Sca
cleaved caspase-3 and PAR accumulation. Values are the mean ± SEM of seve
asterisks *P <0.05; **P <0.01; ***P <0.001 (Kruskal-Wallis, Dunn’s post-test). C: c
100 μM Zaprinast with 2 μg/mL Infliximab. TUNEL, terminal deoxynucleotidil tANOVA Newman-Keuls post-test, P <0.0001). No signifi-
cant changes were found in explants treated only with
Infliximab (0.91 ± 0.06 arbitrary units).
As shown in Figure 2, Infliximab significantly reduced
the number of TUNEL-positive cells in Zaprinast-treated
explants from 7.0 ± 0.7% to 2.2 ± 0.3% (Kruskal-Wallis,
Dunn’s post-test, P <0.001) (Figure 2A). As shown in
Table 3, this reduction occurred mainly in the outer
nuclear layer (ONL).
As mentioned above, TNFα can trigger programmed cell
death by activating the extrinsic and intrinsic apoptotic
pathways that converges on the execution pathway, which
is initiated by the cleavage of caspase-3 [31]. The activity of
caspase-3 in Zaprinast-treated explants was 2.3 ± 0.2 au/mg
protein (ANOVA Newman-Keuls post-test, P <0.01) and
1.3 ± 0.2 au/mg protein in control explants. Infliximab
almost normalized caspase-3 activity (1.7 ± 0.2 au/mg
protein) compared to Zaprinast-treated explants (ANOVA
Newman-Keuls post-test, P <0.05) and the percentage of
cleaved caspase-3 positive cells (1.1 ± 0.3%) comparedporcine retina. Retinal explants were incubated with dimethyl
st as described in Methods. Confocal laser scanning micrographs of
oreceptors (pink) (A), cleaved caspase-3 positive cells (red) (B) and PAR
le bar: 50 μm. (D) Bar graphs showing the quantification of TUNEL,
n different cultures. Values that are significantly different are indicated by
ontrol; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 + INF:
ransferase dUTP nick and labeling.
Table 3 Effect of Infliximab treatment on cell death markers in Zaprinast-treated retinal explants
TUNEL-positive cells (%) caspase-3 positive cells (%) PAR content (CF)
Layer C Z100 INF Z100 + INF C Z100 INF Z100 + INF C Z100 INF Z100 + INF
ONL 0.3 ± 0.1 3.0 ± 1.1a 0.4 ± 0.2b 0.2 ± 0.1c 0.07 ± 0.04 0.2 ± 0.1 0.01 ± 0.01b 0.04 ± 0.03c 7,647 ± 676 22,925 ± 5111a 15,982 ± 2,019 24,970 ± 1,807d,e
INL 1.1 ± 0.2 2.5 ± 0.4a 0.8 ± 0.3b 1.1 ± 0.3 0.2 ± 0.1 2.1 ± 0.3a 0.4 ± 0.3b 0.4 ± 0.1c 7,019 ± 1,163 9,348 ± 2,288 11,156 ± 1,879 21,511 ± 2,251c,d,e
GCL 0.7 ± 0.1 2.0 ± 0.4a 0.6 ± 0.3b 1.0 ± 0.3 0.6 ± 0.3 1.3 ± 0.2a 0.3 ± 0.1 0.6 ± 0.2c 9,891 ± 2,011 10,019 ± 2,212 10,204 ± 1,496 17,134 ± 2,274c,e
Note: Kruskal-Wallis test and Dunn’s Multiple Comparisons were used. Values different from control are shown by a(P <0.05). Superscripts represent statistical differences (P <0.05) between bZ100 and INF; cZ100 and
Z100 + INF; dINF and Z100 + INF; eC and Z100 + INF respectively. ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion nuclear layer; PAR, poly(ADP-ribose) polymers; C: control; Z100: 100 μM Zaprinast; INF:
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Dunn’s post-test, P <0.01). Moreover, immunostaining of
cleaved caspase-3 revealed that Infliximab treatment
reduced the percentage of caspase-3 positive cells at all
cell layers (outer, inner and ganglion layer (ONL, INL
and GCL)) (Kruskal-Wallis, Dunn’s post-test, P <0.05)
(Table 3 and Figure 2B).
We have previously observed an over activation of
poly(ADP-ribose) polymerase (PARP) in our model of
porcine retinal degeneration [25]. Moreover, other authors
have described similar results in other animal models of
retinal degeneration [32,33]. Therefore, we investigated
whether TNFα mediated cell death via the PARP pathway.
Accumulation of poly(ADP-ribose) polymers (PAR)
was used to analyze indirectly PARP activity indirectly.
Immunostaining of PAR revealed a significant accumulation
of these polymers in ONL and outer segments (OS) in
Zaprinast-treated explants (Kruskal-Wallis, Dunn’s post-test,
P <0.05) that were not prevented by Infliximab treatment
(Table 3 and Figure 2C). Infliximab treatment increased PAR
accumulation at all cell layers of Zaprinast-treated explants.
Thus, the inhibition of TNFα by Infliximab is not causally
linked to PARP activation, and therefore does not prevent
the secondary PAR accumulation.
To determine whether cleaved caspase-3 or PAR
accumulation co-localize with TUNEL-positive cells, we
performed triple labeling (Figure 3). In Zaprinast-treated
explants PAR immunostaining co-localized with TUNEL-
positive cells in some cells of ONL, in a few cells of the
INL and in several cells of GCL. This co-localization
disappeared after Infliximab treatment in ONL and
GCL but remained in a subset of cells of the INL. PAR
accumulation remained high, and even increased, at
all cell layers, although the number of TUNEL-positive
cells decreased.
However, caspase-3 positive cells did not co-localize
with TUNEL-positive cells except for a subset of cells in
INL in Zaprinast-treated explants. Co-localization of
caspase-3 with TUNEL-positive cells disappeared after
Infliximab treatment but increased co-localization of
caspase-3 with PAR in INL.
Infliximab ameliorates Zaprinast-induced glial activation
in cultured porcine retina
Gliosis commonly involves upregulation of the intermedi-
ate filament protein, GFAP, in Müller glial cells. We
studied whether Zaprinast-induced retinal degeneration
was accompanied by altered glial reactivity, and if it was
the case, whether the blockade of TNFα could prevent it.
In control explants, GFAP were located in the inner half
of the retinal Müller cells and their endfeet (GCL layer).
However, Zaprinast-treated explants exhibited strong
GFAP-positive staining of Müller cells. After PDE6
inhibition, GFAP was massively upregulated throughoutthe retinal explant. After Infliximab treatment the
GFAP-positive labeling was significantly decreased
(Figure 4).
Infliximab partially prevents Zaprinast-induced oxidative
stress in cultured porcine retina
cGMP accumulation induces oxidative stress in murine
models of retinal degeneration [34] as it does in our model
of porcine retina treated with Zaprinast [25]. To explore
whether Infliximab also prevented Zaprinast-induced
oxidative damage in cultured porcine retina, we measured
intracellular nitrite formation (iNOX), as stable NO
metabolite, TBARS content as indicator of MDA and
total antioxidant capacity (TAC).
As shown in Figure 5, Infliximab normalized TAC but
did not prevent oxidative stress in Zaprinast-treated
explants. Total antioxidant capacity returned to control
level (230 ± 15 μmol/mg protein, ANOVA Newman-Keuls
post-test, P <0.05) (Figure 5A), but TBARS formation
(Figure 5B) and intracellular NOX (Figure 5C) remained
high after the blockade of TNFα.
Discussion
Abnormal pathological pathways such as oxidative stress
and inflammation, including upregulation of TNFα, have
been described in retinal neurodegenerative diseases both
affecting the outer retina, such as RP and age-related
macular degeneration (AMD), and the inner retina, such
as glaucoma and ischemic retinopathy [35-39]. Low-grade
inflammation is present in AMD and glaucoma. For
instance, in AMD, many mediators of chronic low-grade
inflammation such as C-reactive protein, immunoglobulins,
and acute phase molecules, the complement-related
proteins, autoantibodies, macrophage infiltration and
microglial activation have been found [40]. In glaucoma,
microglial activation and an inflammatory response involv-
ing Toll-like receptors (TLRs), complement molecules and
cytokines, such as TNFα and IL-1β, is associated with sec-
ondary phase of the disease [41]. Much less is known about
the inflammatory response to retinal ischemic-reperfusion
(IR) injury. However, pro-inflammatory gene upregulation,
accumulation of leukocytes, and microglial activation is
found following IR in rodent retinas [42].
In RP, retinal degeneration is caused by various mutations
that result in rod death followed by gradual death of
cones [43]. Growing evidence suggests that, regardless
of the causative mutation, neuroinflammation contributes
to photoreceptor degeneration [44,45]. For instance,
different animal models of RP (rdsmice, rd1 mice, P23 rats,
RCS rats) carrying mutations in different genes (Prph2,
PDE6, Rho, Mertk) show signals of an inflammatory process
[23,46-49]. In early stages of retinal degeneration the photo-
receptor cells and surrounding cells, such as microglia,
respond to unfavourable conditions with the production of
Figure 3 Co-localization of caspase-3, PAR and TUNEL at different nuclear layers in culture of porcine retina. Triple-imnunofluorescence
labeling of retinal explants treated with dimethyl sulfoxide (DMSO), Zaprinast and Infliximab alone or combined with Zaprinast was carried out as
described in Methods. Confocal laser scanning micrographs of retinal sections showing immunolocalization of TUNEL (red), cleaved caspase-3
(blue) and PAR (green)-positive cells in the nuclear layers of retina. Scale bar: 10 μm. GCL: ganglion nuclear layer; INL: inner nuclear layer; ONL:
outer nuclear layer; OS: outer segments; C: control; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 + INF: 100 μM Zaprinast with 2 μg/mL
Infliximab. TUNEL, terminal deoxynucleotidil transferase dUTP nick and labeling.
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attempt to protect neurons and to preserve retinal
function. As disease progresses, sustained inflamma-
tory mediators and others such as oxidative stress may
exacerbate photoreceptor cell death and RP progression.
Early studies suggested the presence of immune reactivity
in RP patients, including the presence of retinal autoanti-
bodies in blood and lymphocytes in vitreous humor.
However, these results were variable, maybe due to
the inherent genetic heterogeneity of this disease [36].
Afterwards, microglial activation, a common hallmark
of both inherited and induced retinal degeneration,was described in RP patients and murine models of RP
[12,45,50-53]. It has been shown that microglial activation
leads to proliferation, followed by migration to damaged
sites and release of cytokines (TNFα, IL-1α, IL-1β) chemo-
kines, neurotrophins, glutamate, NO, superoxide anions
and prostaglandins to repair tissue damage. Although
these events are triggered to prevent cell damage,
sustained high levels of these molecules, especially
cytokines, can cause progressive neurodegeneration.
In models of RP, microglial activation coincides, or
precedes, the peak of photoreceptor cell death and with
high levels of TNFα [12,44,45,50,54,55] that seems to be
Figure 4 Infliximab prevents Zaprinast-induced glial fibrillary acidic protein (GFAP) overexpression in cultured porcine retina. Retinal
explants were incubated with dimethyl sulfoxide (DMSO), Zaprinast and Infliximab alone or combined with Zaprinast as described in Methods.
(A) Confocal laser scanning micrographs of retinal sections showing GFAP content. Scale bar: 50 μm. (B) Bar graphs showing the quantification
of GFAP content. Values are the mean ±SEM of six different cultures. Values that are significantly different are indicated by asterisks *P <0.05,
**P <0.01, ***P <0.001 (Kruskal-Wallis, Dunn’s post-test). C: control; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 +INF: 100 μM Zaprinast
with 2 μg/mL Infliximab.
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glial inhibition reduces photoreceptor cell death, TNFα
content and improves visual function [46].
In our human study we confirmed (1) the presence of
high levels of TNFα and IL-6 in aqueous humor in a larger
population of RP patients than previously reported [11];
and we observed that (2) RP patients with higher TNFα
values show better visual function (visual field). The
conflictive positive correlation, between TNFα and
better visual function, may be due to the different
stage of the disease of the patients. It has been shown that
an increase of proinflammatory markers, including TNFα,
in mice models of RP occurs just before photoreceptor cell
loss [12]. Therefore, it is tempting to speculate that at
early onset of RP, when proinflammatory markers are
elevated, visual function is better in patients, and after
these stages patients lose visual function in parallel
with TNFα decrease. In any case, these conflicting,
and interesting, results strongly suggest that further
studies are needed for clarification.
In the last few years, TNFα has been widely recognized as
an attractive therapeutic target for the treatment of retinal
diseases. Different types of monoclonal antibodies against
TNFα, such as Infliximab, Adalimumab, Certolizumab
pegol and Golimumab, or circulating receptor fusion
protein, such as Etanercept, have been used to treat glau-
coma [56,57], ischemic retinopathy [58] or AMD [59].
The role of TNFα in photoreceptor degeneration and
the possible therapeutic use of antibodies against TNFαin the treatment of RP or other retinal degenerations
remain quite unexplored. Based on previous studies
we decided to evaluate the potential protective effect
of the blockade of TNFα in an experimental porcine
model of retinal degeneration. In a previous report we
demonstrated that this porcine model recapitulated some
aspects, especially those related to oxidative stress
and inflammation, of the retinal degeneration observed in
small animals after PDE inhibition [60,61] and RP patients
[8,11]. Sustained elevation of intracellular cGMP in
porcine retinal explants triggered different downstream
effectors of cell death related to caspase-dependent mech-
anisms (caspase-3) and caspase-independent mechanisms
(calpain-2 and probably PARP activity) [25].
Our current study demonstrated that retinal degeneration
accompanied by upregulation of TNFα and IL-6, GFAP
and oxidative damage was ameliorated by blocking TNFα
with Infliximab. Under our experimental conditions,
Infliximab reduced retinal degeneration in all cell
layers, mainly in the ONL, by decreasing the number of
TUNEL-positive cells, supporting the idea that inflamma-
tion plays an important role in the processes of cell death.
We found that Infliximab reduced caspase-3 activity and
the number of cleaved caspase-3 positive cells across the
different cell layers, especially at the INL. Co-localization
studies of caspase-3 and PAR with TUNEL assay sug-
gested that TNFα is promoting cell death through
caspase-independent mechanisms in ONL and GCL and
caspase-dependent mechanisms in INL.
Figure 5 Infliximab partially prevents Zaprinast-induced
oxidative stress in cultures of porcine retina. Retinal explants were
incubated with dimethyl sulfoxide (DMSO), Zaprinast and Infliximab
alone or combined with Zaprinast as described in Methods. Effect
of Infliximab on the total antioxidant capacity (A), TBARS formation
(B) and intracellular NOX (C). Each sample was measured in
duplicate, and the values are the mean ±SEM of eight cultures.
ANOVA Newman-Keuls post-test was used for TAC analysis.
Kruskal-Wallis test and Dunn’s post-test was used for TBARS and iNOX
analysis. *P <0.05, **P <0.01. C: control; Z100: 100 μM Zaprinast; INF:
2 μg/mL Infliximab; Z100 +INF: 100 μM Zaprinast with 2 μg/mL
Infliximab. iNOX, intracellular nitrites and nitrates; TAC, total antioxidant
capacity; TBARS, thiobarbituric acid reactive substances.
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outcomes, each of which is initiated by different signaling
complexes: the apoptosis mode and the necrosis mode.The apoptosis mode includes the extrinsic pathway, mainly
mediated by caspases, and the intrinsic or mitochondrial
pathway, that rely on the balance between the pro-
apoptotic and the anti-apoptotic proteins from the Bcl-2
family. Both pathways converge on the same execution
pathway. The execution pathway is initiated by the
cleavage of caspase-3 and results in DNA fragmentation
and cell death.
We measured indirect activation of PARP through quan-
tification of PAR accumulation. We found an upregulation
of PAR due to PDE6 inhibition. However, blockade of
TNFα did not prevent PAR accumulation but also
increased it. PAR polymers are mainly degraded by poly
(ADP-ribose) glycohydrolase (PARG) enzymes, some of
them activated by caspase-3 cleavage [62]. On the other
hand, PARP can be inactivated by caspase-3 cleavage [63].
Therefore, the inhibition of caspase-3 induced by Infliximab
could inhibit PARG activity and prevent PARP inactivation
thus exacerbating PAR accumulation at all cell layers of
retinal explants. These results support that PARP pathway
is independent of TNFα-associated pathways in this experi-
mental model of retinal degeneration (Figure 6).
These results were supported by previous reports in
which reactive gliosis (GFAP overexpression) induced by
exogenous TNFα was prevented by Adalimumab, other
monoclonal anti-TNFα, in a similar model of organotypic
culture of porcine neuroretina [64]. Activated Müller cells
can release antioxidants, growth factors, and cytokines,
including TNFα, contributing to retinal regeneration or to
neurodegeneration. Müller cells are activated in models of
RP [49,65-68] resulting in overexpression of GFAP,
translocation of Müller cell bodies to the outer retina
and thickening of their processes [69].
As previously shown, retinal degeneration induced by
PDE inhibition was accompanied by oxidative stress in
porcine retinas [25]. This is consistent with the idea that
oxidative stress is also contributing to the progression of
RP in animal models [70-72] and RP patients [8]. In the
current study, we demonstrated that Infliximab partially
prevented antioxidant defense depletion but not oxidative
stress markers. Infliximab normalized the total antioxidant
capacity in Zaprinast-treated explants, but it failed to
return TBARS and NOX to control levels. In retinas of
rd10 mice antioxidant treatment reduced inflammatory
mediators and photoreceptor cell loss [12]. Based on these
data, it is tempting to speculate that the low Infliximab
effect could be due to oxidative stress preceding
upregulation of inflammatory mediators [12,73-75]. The
other possibility is that Infliximab affects other oxidative
stress markers that we did not measure in this study.
Anyway, further studies will be needed to explore this
issue in more depth.
In summary, our results corroborate that RP patients have
ocular inflammation and that TNFα plays an important role
Figure 6 Diagram showing the possible mechanism of Infliximab in the porcine retinal degeneration model. PDE6 inhibition induces
cGMP accumulation and triggers retinal degeneration. The degeneration is accompanied by upregulation of inflammatory mediators, PARP
pathway, reactive gliosis and oxidative stress markers. According to the current study, TNFα may be involved in the retinal degeneration by
increasing caspase-3 activation and reactive gliosis. Infliximab may prevent cell death by inhibiting caspase-dependent pathways that converge in
caspase-3 activation in the INL. Infliximab also may prevent cell death by caspase-independent pathways that remain unclear in the ONL and
GCL. Moreover, Infliximab may exacerbate PARP over activation probably through the caspase-3 inhibition. This over activation could contribute
to the future cell death. cGMP: cyclic GMP; GCL, ganglion nuclear layer; GFAP: glial fibrillary acidic protein; INL, inner nuclear layer; NO: nitric oxide;
ONL, outer nuclear layer; PAR: poly(ADP-ribose) polymers; PARG: poly(ADP-ribose) glycohydrolase; PARP: poly(ADP)ribose polymerase; PDE6:
phosphodiesterase 6; TAC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substances; TNFα: tumor necrosis factor alpha.
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cultured porcine retinas. The mechanisms of cell death vary
in the distinct cell layers. TNFα is involved in retinal degen-
eration through caspase-3 activation, caspase-independent
mechanisms and reactive gliosis. Our data suggest that
other unknown molecules must be contributing to TNFα-
mediated cell death in this model. On the other hand, PARP
activation is independent of TNFα signaling and it is prob-
ably responsible for a future cell death in ONL. The exist-
ence of several distinct pathways that trigger programmed
cell death implies that an efficient protection requires their
simultaneous interruption via combined therapies.
The experimental model of organotypic culture has its
own limitations because it involves transection of the opticnerve and mechanical retinal detachment causing retro-
grade retinal ganglion cell degeneration. To minimize this
problem, we have used detached retinas as controls.
Moreover, the model cannot recapitulate the whole
chronic nature of the degeneration, but we believe that it
could be useful for studying some aspects related to the
retinal degeneration. In our case, we believe that it may
provide a helpful model to design and assay some
treatments, such as Infliximab, thus replacing or reducing
animal experiments. The use of this model allowed us to
evaluate the effect of Infliximab faster and more cheaply
than using the available in vivo models of RP.
The current model of retinal degeneration allowed us to
describe an interesting and, in our opinion, neuroprotective
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http://www.jneuroinflammation.com/content/11/1/172effect of Infliximab that strongly encourages further
exploration using other experimental models. Due to the
importance of the inflammatory process in the pathogenesis
of several retinal degenerative conditions such as RP, AMD,
ischemic retinopathy, or glaucoma, targeting inflammation
could be a promising therapeutic strategy. In particular,
TNFα blockers could be a new therapeutic strategy for the
treatment of RP and other retinal degenerative conditions.
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